文献速递淋巴瘤

套细胞淋巴瘤一线治疗后伊布替尼维持治疗研究

Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

本研究评估初治套细胞淋巴瘤患者诱导治疗后伊布替尼维持治疗(I-M)的安全性和有效性。36例患者接受伊布替尼560 mg每日一次最长4年,3年无进展生存率和总生存率分别为94%和97%。最常见治疗相关不良事件为感染(31例,86%),通常为低级别。

要点

  • 36例初治套细胞淋巴瘤患者一线化疗免疫治疗后接受伊布替尼维持治疗560 mg每日一次最长4年。
  • 中位随访55.7个月,3年无进展生存率和总生存率分别为94%和97%。
  • 最常见治疗相关不良事件为感染(31例,86%),通常为低级别;最常见3/4级毒性为血液学毒性。

核心结论

  • 伊布替尼维持治疗在套细胞淋巴瘤一线化疗免疫治疗后可行,毒性可控但显著。
  • 维持治疗期间少数患者出现NGS-MRD变化,进展和生存事件较少。

研究设计与样本

  • 评估初治套细胞淋巴瘤患者诱导治疗后伊布替尼维持治疗安全性和有效性的研究。
  • 36例对一线化疗免疫治疗±自体干细胞移植达到完全缓解或部分缓解的套细胞淋巴瘤患者接受伊布替尼560 mg每日一次最长4年。
  • 主要目标为自伊布替尼维持治疗开始计算的3年无进展生存率。
  • 在外周血中采用下一代测序(NGS)检测微小残留病(MRD),于伊布替尼维持治疗开始前及开始后1、6、18至24个月进行评估。

主要发现

  • 36例患者中位年龄60岁(范围46-90岁),18例(50%)在第一次完全缓解时接受自体干细胞移植巩固后进入伊布替尼维持治疗。
  • 中位随访55.7个月,17例(47%)完成全程伊布替尼维持治疗(中位37.5个周期;范围2-52)。
  • 3年无进展生存率和总生存率分别为94%和97%。
  • 有既往自体干细胞移植的患者3年无进展生存率和总生存率均为100%。
  • 22例接受MRD评估的患者诱导后均为MRD阴性;6例在伊布替尼维持治疗期间转为MRD阳性,其中2例继续伊布替尼维持治疗后恢复MRD阴性,除1例疾病进展外均维持影像学完全缓解。

关键数值与推荐

  • 伊布替尼维持治疗剂量为560 mg每日一次,最长4年。
  • 最常见治疗相关不良事件为感染(31例,86%),通常为低级别;最常见3/4级毒性为血液学毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Maintenance rituximab in mantle cell lymphoma (MCL) has improved survival and supports exploration of maintenance with novel agents. We evaluated the safety and efficacy of ibrutinib maintenance (I-M) after induction in patients with treatment-naive MCL. Patients with MCL with complete response (CR) or partial response to frontline chemoimmunotherapy ± autologous stem cell transplantation (auto-SCT) received I-M 560 mg daily for up to 4 years. Primary objective was 3-year progression-free survival (PFS) rate from initiation of I-M. Minimal residual disease (MRD) assessments by next-generation sequencing (NGS) on peripheral blood were measured before I-M initiation and at 1, 6, and 18 to 24 months after initiation. Among 36 patients, the median age was 60 years (range, 46-90). For frontline treatment, 18 patients (50%) had consolidation with auto-SCT in CR1 before I-M. At median follow-up of 55.7 months, 17 patients (47%) completed full course I-M (median, 37.5 cycles; range, 2-52). The 3-year PFS and overall survival (OS) rates were 94% and 97%, respectively. With prior auto-SCT, 3-year PFS and OS rates were both 100%. The most common treatment-related adverse event with I-M was infection (n = 31; 86%), typically low grade; the most common grade 3/4 toxicities were hematologic. In 22 patients with MRD assessments, all were MRD negative after induction. Six became MRD positive on I-M, with 2 reverting to MRD-negative status with continued I-M, and all maintain radiographic CR with the exception of 1 with disease progression. I-M is feasible in MCL after frontline chemoimmunotherapy with manageable toxicities although significant. Changes in NGS-MRD were noted in limited patients during maintenance with few progression and survival events. This trial was registered at www.clinicaltrials.gov as #NCT02242097.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karmali R, Abramson JS, Stephens DM, et al. Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 2023. PMID: 37756532. doi:10.1182/bloodadvances.2023011271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。